Phathom Pharmaceuticals Q2 2024 Adj. EPS $(1.25) Beats $(1.38) Estimate, Sales $7.324M Beat $5.809M Estimate
Portfolio Pulse from Benzinga Newsdesk
Phathom Pharmaceuticals reported its Q2 2024 results, with an adjusted EPS of $(1.25), beating the estimate of $(1.38). Sales were $7.324 million, surpassing the expected $5.809 million.
August 08, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Phathom Pharmaceuticals reported better-than-expected Q2 2024 results, with an adjusted EPS of $(1.25) beating the $(1.38) estimate and sales of $7.324 million surpassing the $5.809 million estimate.
The better-than-expected EPS and sales figures are likely to positively impact PHAT's stock price in the short term as they indicate stronger financial performance than anticipated.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100